Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) (TA570)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 20 March 2019
Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma (TA562)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 27 February 2019
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (TA558)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 23 January 2019
Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (TA553)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 19 December 2018
Avelumab for treating metastatic Merkel cell carcinoma (TA517)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 11 April 2018
Vismodegib for treating basal cell carcinoma (TA489)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 22 November 2017
Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 12 September 2017Published date: 25 November 2015
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 12 September 2017Published date: 7 October 2015
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (TA473)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 31 August 2017
Suspected cancer: recognition and referral (NG12)Product type:GuidanceProgramme:NICE guidelineLast updated: 26 July 2017Published date: 23 June 2015
Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA414)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 26 October 2016
Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 28 September 2016
Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 27 July 2016
Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 22 June 2016
Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 18 February 2016
Skin cancer prevention (PH32)Product type:GuidanceProgramme:Public health guidelineLast updated: 9 February 2016Published date: 26 January 2011
Sunlight exposure: risks and benefits (NG34)Product type:GuidanceProgramme:NICE guidelinePublished date: 9 February 2016
VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions (DG19)Product type:GuidanceProgramme:Diagnostics guidancePublished date: 11 November 2015
Melanoma: assessment and management (NG14)Product type:GuidanceProgramme:NICE guidelinePublished date: 29 July 2015
Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma (TA269)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 1 January 2015Published date: 12 December 2012
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma (TA321)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 22 October 2014
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 23 July 2014
Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma (IPG478)Product type:GuidanceProgramme:Interventional procedures guidancePublished date: 26 February 2014
Electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma (IPG446)Product type:GuidanceProgramme:Interventional procedures guidancePublished date: 27 March 2013
Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (TA268)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 12 December 2012
Ambulight PDT for the treatment of non-melanoma skin cancer (MTG6)Product type:GuidanceProgramme:Medical technologies guidancePublished date: 25 July 2011
Endoscopic radical inguinal lymphadenectomy (IPG398)Product type:GuidanceProgramme:Interventional procedures guidancePublished date: 22 June 2011
Improving outcomes for people with skin tumours including melanoma (CSG8)Product type:GuidanceProgramme:Cancer service guidelinePublished date: 22 February 2006
Photodynamic therapy for non-melanoma skin tumours (including premalignant and primary non-metastatic skin lesions) (IPG155)Product type:GuidanceProgramme:Interventional procedures guidancePublished date: 22 February 2006
Suspected cancer (QS124)Product type:Quality standardLast updated: 5 December 2017Published date: 30 June 2016
GatewayC: Improving early detection of cancer through e-learning for primary careProduct type:Shared learningPublished date: 31 January 2019
Overcoming the challenges of implementing the new NICE guidance for suspected cancer: recognition and referralProduct type:Shared learningPublished date: 8 January 2017
Setting up an effective and efficient sentinel lymph node biopsy service for malignant melanoma within the NHSProduct type:Shared learningPublished date: 29 July 2015